CLINICAL TRIALS PROFILE FOR DUPILUMAB

All Clinical Trials for dupilumab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01312961 ↗	Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma	Completed	Regeneron Pharmaceuticals	Phase 2	2011-03-01	Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma. Secondary Objectives: - To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. - To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
NCT01312961 ↗	Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma	Completed	Sanofi	Phase 2	2011-03-01	Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma. Secondary Objectives: - To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. - To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
NCT01385657 ↗	Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis	Completed	Sanofi	Phase 1	2011-07-31	The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
NCT01385657 ↗	Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis	Completed	Regeneron Pharmaceuticals	Phase 1	2011-07-31	The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
NCT01548404 ↗	Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis	Completed	Sanofi	Phase 2	2012-04-01	The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).

Clinical Trial Conditions for dupilumab

Condition Name

Condition Name for dupilumab
Intervention	Trials
Atopic Dermatitis	41
Asthma	22
Dermatitis, Atopic	8
Chronic Rhinosinusitis With Nasal Polyps	6

Condition MeSH

Condition MeSH for dupilumab
Intervention	Trials
Dermatitis	60
Dermatitis, Atopic	56
Eczema	54
Asthma	25

Clinical Trial Locations for dupilumab

Trials by Country

Trials by Country for dupilumab
Location	Trials
United States	956
Canada	120
Japan	114
Germany	86
Poland	85

Trials by US State

Trials by US State for dupilumab
Location	Trials
California	60
Florida	46
New York	45
Texas	44
Pennsylvania	39

Clinical Trial Progress for dupilumab

Clinical Trial Phase

Clinical Trial Phase for dupilumab
Clinical Trial Phase	Trials
Phase 4	42
Phase 3	43
Phase 2/Phase 3	5

Clinical Trial Status

Clinical Trial Status for dupilumab
Clinical Trial Phase	Trials
Recruiting	56
Completed	41
Not yet recruiting	32

Clinical Trial Sponsors for dupilumab

Sponsor Name

Sponsor Name for dupilumab
Sponsor	Trials
Regeneron Pharmaceuticals	95
Sanofi	80
National Institute of Allergy and Infectious Diseases (NIAID)	8

Sponsor Type

Sponsor Type for dupilumab
Sponsor	Trials
Industry	192
Other	79
NIH	9